Inhibition of PKC β by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients

Investigative Ophthalmology and Visual Science

Volumn 47, Issue 1, 2006, Pages 86-92

  Aiello, Lloyd Paul ^a,b   Clermont, Allen ^a   Arora, Vipin ^c   Davis, Matthew D ^d   Sheetz, Matthew J ^c   Bursell, Sven Eric ^a  

^a JOSLIN DIABETES CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RUBOXISTAURIN; ENZYME INHIBITOR; INDOLE DERIVATIVE; MALEIMIDE DERIVATIVE; PROTEIN KINASE C; PROTEIN KINASE C BETA;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CIRCULATION TIME; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC RETINOPATHY; DRUG DOSE INCREASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEMODYNAMICS; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LABORATORY TEST; MALE; NEUTROPENIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; RETINA BLOOD FLOW; ADOLESCENT; BLOOD FLOW VELOCITY; BLOOD RETINA BARRIER; COMPARATIVE STUDY; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; DRUG EFFECT; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PHYSIOLOGY; RETINA BLOOD VESSEL;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; BLOOD FLOW VELOCITY; BLOOD-RETINAL BARRIER; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; INDOLES; MALE; MALEIMIDES; MIDDLE AGED; PROTEIN KINASE C; RETINAL VESSELS;

EID: 33644842187     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.05-0757     Document Type: Article

References (31)

1. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33): UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837-853.
3. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103-117.
4. Inoguchi T, Battan R, Handler E, et al. Preferential elevation of protein kinase C isoform β II and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci USA. 1992;89:11059-11063.
5. Xia P, Inoguchi T, Kern TS, et al. Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia. Diabetes. 1994;43:1122-1129.
6. Shiba T, Inoguchi T, Sportsman JR, et al. Correlation of diacylglycerol level and protein kinase C activity in rat retina to retinal circulation. Am J Physiol. 1993;265:E783-E793.
7. Craven PA, DeRubertis FR. Protein kinase C is activated in glomeruli from streptozotocin diabetic rats: possible mediation by glucose. J Clin Invest. 1989;83:1667-1675.
8. Nishikawa T, Edelstein D, Du XL, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. 2000;404:787-790.
9. Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes. 1998;47:859-866.
10. Cotter MA, Jack AM, Cameron NE. Effects of the protein kinase C β inhibitor LY333531 on neural and vascular function in rats with streptozotocin-induced diabetes. Clin Sci. 2002;103:311-321.
11. Yan SF, Lu J, Zou YS, et al. Protein kinase C-beta and oxygen deprivation: a novel Egr-1-dependent pathway for fibrin deposition in hypoxemic vasculature. J Biol Chem. 2000;275:11921-11928.
12. Nagpala PG, Malik AB, Vuong PT, Lum H. Protein kinase C beta 1 overexpression augments phorbol ester-induced increase in endothelial permeability. J Cell Physiol. 1996;166:249-255.
13. Wolf BA, Williamson JR, Easom RA, et al. Diacylglycerol accumulation and microvascular abnormalities induced by elevated glucose levels. J Clin Invest. 1991;87:31-38.
14. Xia P, Aiello LP, Ishii H, et al. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest. 1996;98:2018-2026.
15. Funatsu H, Yamashita H, Ikeda T, et al. Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology. 2003;110:1690-1696.
16. Suzuma K, Takahara N, Suzuma I, et al. Characterization of protein kinase C beta isoform's action on retinoblastoma protein phosphorylation, vascular endothelial growth factor-induced endothelial cell proliferation, and retinal neovascularization. Proc Natl Acad Sci USA. 2002;99:721-726.
17. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480-1487.
18. Aiello LP, Bursell SE, Clermont A, et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective β-isoform-selective inhibitor. Diabetes. 1997;46:1473-1480.
19. Jirousek MR, Gillig JR, Gonzalez CM, et al. (S)-13-[(dimethylamino) methyl]-10,11,14,15-tetrahydro-4,9:16,21-dimetheno-1H,13H-dibenzo[e,k]pyrrolo[3, 4-H][1,4,13]oxadiazacyclohexadecene-1,3(2H)-dione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C β. J Med Chem. 1996;39:2664-2671.
20. Engel GL, Farid NA, Faul MM, Richardson LA, Winneroski LL. Salt form selection and characterization of LY333531 mesylate monohydrate. Int J Pharm. 2000;198:239-247.
21. Ishii H, Jirousek MR, Koya D, et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC β-inhibitor. Science. 1996;272:728-731.
22. Danis RP, Bingaman DP, Jirousek M, Yang Y. Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKC β; inhibition with LY333531. Invest Ophthalmol Vis Sci. 1998;39:171-179.
23. Nonaka A, Kiryu J, Tsujikawa A, et al. PKC β inhibitor (LY333531) attenuates leukocyte entrapment in retinal microcirculation of diabetic rats. Invest Ophthalmol Vis Sci. 2000;41:2702-2706.
24. The PKC-DRS Study Group. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial. Diabetes. 2005;54:2188-2197.
25. Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Ophthalmology. 1991;98:823-833.
26. Bursell SE, Clermont AC, Kinsley BT, et al. Retinal blood flow changes in patients with insulin-dependent diabetes mellitus and no diabetic retinopathy. Invest Ophthalmol Vis Sci. 1996;37:886-897.
27. Campochiaro PA, C99-PKC412-003 Study Group. Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412. Invest Ophthalmol Vis Sci. 2004;45:922-931.
28. Koya D, Haneda M, Nakagawa H, et al. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC β; inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J. 2000;14:439-447.
29. Kelly DJ, Zhang Y, Hepper C, et al. Protein kinase C β inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension. Diabetes. 2003;52:512-518.
30. Aiello LP. The potential role of PKC β in diabetic retinopathy and macular edema. Surv Ophthalmol. 2002;47:S263-S269.
31. Eli Lilly Press Release. Available at http://newsroom.lilly.com/ ReleaseDetail.cfm. Accessed August 26, 2005.